Deferiprone in iron overload

Jayesh Mehta; Seema Singhal; B. C. Mehta; D. Adhikari; A. V. Hoffbrand; B. Wonke; D. G. Nathan

doi:10.1056/NEJM199508313330915

Deferiprone in iron overload

Jayesh Mehta^*, Seema Singhal, B. C. Mehta, D. Adhikari, A. V. Hoffbrand, B. Wonke, D. G. Nathan

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Abstract

To the Editor: Olivieri et al. (April 6 issue)¹ are to be congratulated on their work on deferiprone, which, in addition to demonstrating the drug's efficacy in iron chelation, is the only study so far to have addressed some of the controversies surrounding the use of the drug.²–⁵ Our experience with autoimmune phenomena has not been confined to just one case of fatal drug-induced systemic lupus erythematosus.² We have found a significantly higher incidence of antinuclear antibodies in patients with thalassemia treated with deferiprone (7 of 27) than in those not receiving the drug (2 of 63, P<0.01). Antibodies.

Original language	English (US)
Pages (from-to)	597-599
Number of pages	3
Journal	New England Journal of Medicine
Volume	333
Issue number	9
DOIs	https://doi.org/10.1056/NEJM199508313330915
State	Published - Aug 31 1995

ASJC Scopus subject areas

Medicine(all)

Access to Document

10.1056/NEJM199508313330915

Fingerprint Dive into the research topics of 'Deferiprone in iron overload'. Together they form a unique fingerprint.

Cite this

@article{e759d3356a934c96b50e955da62c62ba,

title = "Deferiprone in iron overload",

abstract = "To the Editor: Olivieri et al. (April 6 issue)1 are to be congratulated on their work on deferiprone, which, in addition to demonstrating the drug's efficacy in iron chelation, is the only study so far to have addressed some of the controversies surrounding the use of the drug.2–5 Our experience with autoimmune phenomena has not been confined to just one case of fatal drug-induced systemic lupus erythematosus.2 We have found a significantly higher incidence of antinuclear antibodies in patients with thalassemia treated with deferiprone (7 of 27) than in those not receiving the drug (2 of 63, P<0.01). Antibodies.",

author = "Jayesh Mehta and Seema Singhal and Mehta, {B. C.} and D. Adhikari and Hoffbrand, {A. V.} and B. Wonke and Nathan, {D. G.}",

year = "1995",

month = aug,

day = "31",

doi = "10.1056/NEJM199508313330915",

language = "English (US)",

volume = "333",

pages = "597--599",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "9",

}

TY - JOUR

T1 - Deferiprone in iron overload

AU - Mehta, Jayesh

AU - Singhal, Seema

AU - Mehta, B. C.

AU - Adhikari, D.

AU - Hoffbrand, A. V.

AU - Wonke, B.

AU - Nathan, D. G.

PY - 1995/8/31

Y1 - 1995/8/31

N2 - To the Editor: Olivieri et al. (April 6 issue)1 are to be congratulated on their work on deferiprone, which, in addition to demonstrating the drug's efficacy in iron chelation, is the only study so far to have addressed some of the controversies surrounding the use of the drug.2–5 Our experience with autoimmune phenomena has not been confined to just one case of fatal drug-induced systemic lupus erythematosus.2 We have found a significantly higher incidence of antinuclear antibodies in patients with thalassemia treated with deferiprone (7 of 27) than in those not receiving the drug (2 of 63, P<0.01). Antibodies.

AB - To the Editor: Olivieri et al. (April 6 issue)1 are to be congratulated on their work on deferiprone, which, in addition to demonstrating the drug's efficacy in iron chelation, is the only study so far to have addressed some of the controversies surrounding the use of the drug.2–5 Our experience with autoimmune phenomena has not been confined to just one case of fatal drug-induced systemic lupus erythematosus.2 We have found a significantly higher incidence of antinuclear antibodies in patients with thalassemia treated with deferiprone (7 of 27) than in those not receiving the drug (2 of 63, P<0.01). Antibodies.

UR - http://www.scopus.com/inward/record.url?scp=0029655177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029655177&partnerID=8YFLogxK

U2 - 10.1056/NEJM199508313330915

DO - 10.1056/NEJM199508313330915

M3 - Letter

C2 - 7623918

AN - SCOPUS:0029655177

VL - 333

SP - 597

EP - 599

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 9

ER -